|Bid||216.88 x 10000|
|Ask||217.02 x 3400|
|Day's range||216.20 - 218.98|
|52-week range||176.68 - 257.76|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||43.66|
|Earnings date||19 Aug 2021|
|Forward dividend & yield||2.80 (1.29%)|
|Ex-dividend date||23 Sept 2021|
|1y target est||223.02|
Shareholders will probably not be disappointed by the robust results at Cochlear Limited ( ASX:COH ) recently and they...
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval and clearance in the last month for its Cochlear™ Remote Assist solution in the Nucleus® and Baha® Systems. The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution are the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.
How far off is Cochlear Limited ( ASX:COH ) from its intrinsic value? Using the most recent financial data, we'll take...